Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cutia Therapeutics (2487.HK)
HKD2.50
-0.04 (-1.57%)
CN HKSE Healthcare Biotechnology
Address
Huanzhi Building 200070
Shanghai, CN
Shanghai, CN
CEO
Lele Zhang
Website
cutiatx.com
IPO
2023-06-12
ISIN KYG2606C1006
Description
Cutia Therapeutics is a biopharmaceutical firm dedicated to establishing a robust dermatology platform for addressing conditions affecting both the skin and scalp. Its comprehensive therapeutic scope encompasses various dermatological challenges, including medications for localized fat accumulation, advanced care for scalp disorders, treatments for a wide array of skin ailments, and topical pain management. Founded in 2019, the company's main headquarters are situated in Shanghai, China, complemented by additional offices located in Beijing, Wuxi, and Hong Kong.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
HKD2.50
-0.04 (-1.57%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
179.4K
Beta
0.45
Float Shares
40.70M
Free Float %
11.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.46% | -10.03% | -21.96% | -22.29% | -45.27% | -20.93% | -62.91% | -83.64% | -83.64% | -83.64% | -83.64% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
2.50
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-3.21
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+20.2% ★ Q4'25: +161.3% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+27.0% Q4'25: +72.6% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-108.8% Q4'25: -45.5% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-91.8% Q4'25: -36.6% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-74.5% Q4'25: -95.4% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+7.7% Q4'25: +12.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.14× Q4'25: -0.94× (vs Q4'23)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
137.62M
est: 124.50M (+10.5%)
|
279.62M
est: 281.90M (-0.8%)
|
336.15M
est: 472.91M (-28.9%)
|
605.94M
551.65M – 660.23M
+28.1% YoY
|
965.73M
786.64M – 1.14B
+59.4% YoY
|
1.33B
1.13B – 1.53B
+38.0% YoY
|
| EBITDA |
-1.92B
est: -118.70M (-1,514.8%)
|
-430.69M
est: -272.13M (-58.3%)
|
-277.93M
est: -456.52M (+39.1%)
|
-584.95M
-637.36M – -532.54M
-28.1% YoY
|
-932.28M
-1.11B – -759.39M
-59.4% YoY
|
-1.29B
-1.48B – -1.09B
-38.0% YoY
|
| EBIT |
-1.96B
est: -121.83M (-1,508.2%)
|
-461.54M
est: -277.28M (-66.5%)
|
-308.61M
est: -465.16M (+33.7%)
|
-596.01M
-649.41M – -542.61M
-28.1% YoY
|
-949.90M
-1.13B – -773.75M
-59.4% YoY
|
-1.31B
-1.51B – -1.11B
-38.0% YoY
|
| Net Income |
-1.96B
est: -2.60B (+24.6%)
|
-433.81M
est: -529.18M (+18.0%)
|
-340.19M
est: -370.82M (+8.3%)
|
-5.15M
-6.16M – -4.13M
+98.6% YoY
|
49.76M
46.10M – 53.41M
+1,066.7% YoY
|
130.40M
104.71M – 156.09M
+162.1% YoY
|
| SGA |
255.16M
est: 405.92M (-37.1%)
|
299.50M
est: 924.31M (-67.6%)
|
355.75M
est: 1.55B (-77.1%)
|
1.99B
1.81B – 2.16B
+28.1% YoY
|
3.17B
2.58B – 3.75B
+59.4% YoY
|
4.37B
3.71B – 5.03B
+38.0% YoY
|
| EPS |
-6.43
est: -7.87 (+18.3%)
|
-1.41
est: -1.60 (+11.8%)
|
-1.03
est: -1.12 (+8.1%)
|
-0.02
-0.02 – -0.01
+98.6% YoY
|
0.15
0.14 – 0.16
+1,066.7% YoY
|
0.39
0.32 – 0.47
+162.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
41.13M
OE per share TTM
0.12
Owner's Yield
3.34%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
125.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 15.7K | 0.28% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-926.8K
Shares Outstanding
363.37M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yuqing Huang | Chief Financial Officer & Executive Director | 5M | male |
| Lele Zhang | Founder, Chief Executive Officer & Executive Director | 5M | female |
| Jiaru Wu | President of Supporting Platform | — | male |
| Jingxin Xu | President of Manufacturing and Quality Control Department | — | female |
| Chi Kit Leung | Company Secretary | — | male |
| Qi Zhu | Chief Medical Officer | — | male |
| Lei Lei | President of Research and Development Department | — | — |
| Chunna Zhang | President of Regulatory Affairs Department | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2487.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
